Literature DB >> 8806589

Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo.

H Obayashi1, K Nakano, H Shigeta, M Yamaguchi, K Yoshimori, M Fukui, M Fujii, Y Kitagawa, N Nakamura, K Nakamura, Y Nakazawa, K Ienaga, M Ohta, M Nishimura, I Fukui, M Kondo.   

Abstract

Crossline is one of the major advanced glycation end products resulting the reaction mixture of free amino group(s) such as epsilon-one in lysine with D-glucose in vitro. To study crossline formation on proteins in vitro and in vivo, polyclonal antiserum to the crossline hapten was prepared. This antiserum reacted with bovine and human serum albumin that had been modified by prolonged incubation with glucose as well as with crossline itself. Antisera did not react with unmodified serum albumin or the other Maillard-related compounds. Crossline was formed in a time-dependent manner when a mixture of six different proteins was incubated with glucose at pH 7.2 or 9.0. Crossline levels could be measured in rat lens proteins and the levels increased with age. The crossline content of lens proteins in diabetic rats was more than two-fold higher than that of age-matched controls. Results of this study suggest that most proteins containing advanced glycation end products have crossline-like structures. Measurement of crossline-like structures in biological specimens may provide an index of aging and of the development of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806589     DOI: 10.1006/bbrc.1996.1308

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

Review 1.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  Glycated type 1 collagen induces endothelial dysfunction in culture.

Authors:  Pei-Ching Kuo; Cheng-Heng Kao; Jan-Kan Chen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-10-03       Impact factor: 2.416

3.  Skin advanced glycation end products as biomarkers of photosensitivity in schizophrenia.

Authors:  Eriko Tani; Tohru Ohnuma; Hitoki Hirose; Ken Nakayama; Wanyi Mao; Mariko Nakadaira; Narihiro Orimo; Hiroki Yamashita; Yuto Takebayashi; Yasue Miki; Narimasa Katsuta; Shohei Nishimon; Toshio Hasegawa; Etsuko Komiyama; Yasushi Suga; Shigaku Ikeda; Heii Arai
Journal:  Int J Methods Psychiatr Res       Date:  2019-01-31       Impact factor: 4.035

4.  Modulated Protein Binding Ability of Anti-Diabetic Drugs in Presence of Monodispersed Gold Nanoparticles and its Inhibitory Potential towards Advanced Glycated End (AGE) Product Formation.

Authors:  Imocha Rajkumar Singh; Sivaprasad Mitra
Journal:  J Fluoresc       Date:  2020-01-10       Impact factor: 2.217

5.  Inhibiting Effect of Zinc Oxide Nanoparticles on Advanced Glycation Products and Oxidative Modifications: a Potential Tool to Counteract Oxidative Stress in Neurodegenerative Diseases.

Authors:  Jalaluddin M Ashraf; Mohammad Azam Ansari; Sana Fatma; Saleh M S Abdullah; Johar Iqbal; Aymen Madkhali; Al Hassan Hamali; Saheem Ahmad; Ahmed Jerah; Valentina Echeverria; George E Barreto; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2018-02-08       Impact factor: 5.590

6.  Advanced Glycation End-products and Bone Fractures.

Authors:  Deepak Vashishth
Journal:  IBMS Bonekey       Date:  2009-08

7.  Antiglycation and antioxidant activities of mogroside extract from Siraitia grosvenorii (Swingle) fruits.

Authors:  Hesheng Liu; Chengcheng Wang; Xiangyang Qi; Jian Zou; Zhida Sun
Journal:  J Food Sci Technol       Date:  2018-03-14       Impact factor: 2.701

8.  Isolation and characterization of advanced glycation end products derived from the in vitro reaction of ribose and collagen.

Authors:  R G Paul; N C Avery; D A Slatter; T J Sims; A J Bailey
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

9.  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

Authors:  S Y Tang; M R Allen; R Phipps; D B Burr; D Vashishth
Journal:  Osteoporos Int       Date:  2008-10-11       Impact factor: 4.507

Review 10.  Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties.

Authors:  Lamya Karim; Mary L Bouxsein
Journal:  Bone       Date:  2015-07-23       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.